Return to search

Endotis Raises Second Round

Endotis Pharma, a French developer of small-glyco drugs for applications in thrombosis and oncology, has raised EUR 25 million in Series B funding. The Wellcome Trust led the round, and was joined by Endeavour vision, NIF SMBC Ventures and return backers Sofinnova Partners.